08:43:49 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2025-02-26 Bokslutskommuniké 2024
2024-11-27 Kvartalsrapport 2024-Q3
2024-08-28 Kvartalsrapport 2024-Q2
2024-05-22 Kvartalsrapport 2024-Q1
2024-05-02 Ordinarie utdelning ACOU 0.00 SEK
2024-04-30 Årsstämma 2024
2024-02-28 Bokslutskommuniké 2023
2023-11-07 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-31 Kvartalsrapport 2023-Q1
2023-04-26 Ordinarie utdelning ACOU 0.00 SEK
2023-04-25 Årsstämma 2023
2023-02-22 Bokslutskommuniké 2022
2022-11-23 Kvartalsrapport 2022-Q3
2022-08-24 Kvartalsrapport 2022-Q2
2022-05-18 Kvartalsrapport 2022-Q1
2022-04-28 Ordinarie utdelning ACOU 0.00 SEK
2022-04-27 Årsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-12-21 Extra Bolagsstämma 2021
2021-11-24 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-26 Kvartalsrapport 2021-Q1
2021-04-28 Årsstämma 2021
2021-04-15 Ordinarie utdelning ACOU 0.00 SEK
2021-02-24 Bokslutskommuniké 2020
2020-11-25 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-06-10 Ordinarie utdelning ACOU 0.00 SEK
2020-06-09 Årsstämma 2020
2020-05-27 Kvartalsrapport 2020-Q1
2020-02-25 Bokslutskommuniké 2019
2019-11-20 Kvartalsrapport 2019-Q3
2019-08-21 Kvartalsrapport 2019-Q2
2019-06-18 Ordinarie utdelning ACOU 0.00 SEK
2019-06-17 Årsstämma 2019
2019-05-22 Kvartalsrapport 2019-Q1
2019-02-27 Bokslutskommuniké 2018
2018-11-22 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-06-14 Ordinarie utdelning ACOU 0.00 SEK
2018-06-13 Årsstämma 2018
2018-05-16 Kvartalsrapport 2018-Q1
2018-03-21 Extra Bolagsstämma 2018
2018-02-28 Bokslutskommuniké 2017
2017-11-24 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-06-19 Ordinarie utdelning ACOU 0.00 SEK
2017-06-16 Årsstämma 2017
2017-05-15 Kvartalsrapport 2017-Q1
2017-02-28 Bokslutskommuniké 2016
2016-11-25 Kvartalsrapport 2016-Q3

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
AcouSort är verksamt inom medicinteknik. Idag har bolaget en utvecklad plattformsteknologi inriktad mot akustofores, som med hjälp utav ultraljud separerar och analyserar biologiska cellers sammansättningar. Tekniken används huvudsakligen vid analys av cancerfall och sepsis (blodförgiftning). En stor del av forskningen sker i samarbete med övriga aktörer inom Life-Science. Bolaget etablerades under 2010 och har sitt huvudkontor i Lund.
2023-11-27 08:30:00

Today, 27 November 2023, is the last day of trading in the unit rights issued in conjunction with AcouSort AB (publ)'s ("AcouSort" or the "Company") rights issue of units, consisting of shares and warrants, with pre-emption rights for existing shareholders which was resolved by the Board of Directors on 7 November 2023 with the support of the authorization granted by the Annual General Meeting held on 25 April 2023 (the "Rights Issue"). Unit rights that are not sold by today, 27 November 2023, or exercised for subscription of units no later than 30 November 2023, will expire worthless.

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, UNITED KINGDOM, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS WHOLLY OR PARTIALLY SUBJECT TO LEGAL RESTRICTIONS. SEE ALSO THE "IMPORTANT INFORMATION" SECTION BELOW.

The Rights Issue in summary:
  • Subscription period: 16 November - 30 November 2023.
  • Trading in unit rights: 16 November - 27 November 2023.
  • Announcement of outcome: Around 4 December 2023.
  • Pre-emption right: Existing shareholders in AcouSort as of the record date, which was 14 November 2023, were allotted one (1) unit right for each existing share. Twenty-four (24) unit rights entitle the holder to subscribe for one (1) unit in the Rights Issue. One (1) unit consists of three (3) shares and one (1) free of charge warrant of series TO 2 (the "Warrants").
  • Volume: In total, a maximum of 551,998 units will be issued, which means that a maximum of 1,655,994 new shares and 551,998 Warrants will be issued.
  • Subscription price: SEK 45 per unit, corresponding to SEK 15 per share. The Warrants are issued free of charge.
  • Issue proceeds: The Rights Issue will initially provide AcouSort with a maximum of approximately MSEK 24.8 before issuing costs. Upon full subscription and full exercise of all Warrants issued through the Rights Issue, the Company may additionally receive at most MSEK 11.6 before issuing costs.

For complete terms and instructions for the Rights Issue, please refer to the information memorandum published by the Company on 14 November 2023 and which is available on the Company's website (www.acousort.com).

Advisors

Erik Penser Bank AB is the financial advisor and issuing agent and Fredersen Advokatbyrå AB is legal advisor to AcouSort in connection with the Rights Issue.